skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Pretreatment Evaluation of Microcirculation by Dynamic Contrast-Enhanced Magnetic Resonance Imaging Predicts Survival in Primary Rectal Cancer Patients

Abstract

Purpose: To investigate the prognostic value of the perfusion index (PI), a microcirculatory parameter estimated from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), which integrates information on both flow and permeability, to predict overall survival and disease-free survival in patients with primary rectal cancer. Methods and Materials: A total of 83 patients with stage cT3 rectal cancer requiring neoadjuvant chemoradiation were investigated with DCE-MRI before start of therapy. Contrast-enhanced dynamic T{sub 1} mapping was obtained, and a simple data analysis strategy based on the calculation of the maximum slope of the tissue concentration–time curve divided by the maximum of the arterial input function was used as a measure of tumor microcirculation (PI), which integrates information on both flow and permeability. Results: In 39 patients (47.0%), T downstaging (ypT0-2) was observed. During a mean (±SD) follow-up period of 71 ± 29 months, 58 patients (69.9%) survived, and disease-free survival was achieved in 45 patients (54.2%). The mean PI (PImean) averaged over the group of nonresponders was significantly higher than for responders. Additionally, higher PImean in age- and gender-adjusted analyses was strongly predictive of therapy nonresponse. Most importantly, PImean strongly and significantly predicted disease-free survival (unadjusted hazard ratio [HR], 1.85 [ 95% confidence interval, 1.35-2.54; P<.001)]; HR adjustedmore » for age and sex, 1.81 [1.30-2.51]; P<.001) as well as overall survival (unadjusted HR 1.42 [1.02-1.99], P=.040; HR adjusted for age and sex, 1.43 [1.03-1.98]; P=.034). Conclusions: This analysis identifies PImean as a novel biomarker that is predictive for therapy response, disease-free survival, and overall survival in patients with primary locally advanced rectal cancer.« less

Authors:
 [1];  [2]; ;  [3];  [4];  [5];  [6]
  1. Department of Radio-Oncology, Academic Teaching Hospital Feldkirch, Feldkirch (Austria)
  2. Department of Oncology, Wels-Grieskirchen Medical Hospital, Wels (Austria)
  3. Department of Radiology, Innsbruck Medical University, Innsbruck (Austria)
  4. Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch (Austria)
  5. Department of Radio-Oncology, Innsbruck Medical University, Innsbruck (Austria)
  6. Department of Surgery, Paracelsus Medical University, Salzburg (Austria)
Publication Date:
OSTI Identifier:
22420509
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 90; Journal Issue: 5; Other Information: Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; BIOLOGICAL MARKERS; CONTRAST MEDIA; DATA ANALYSIS; HAZARDS; NEOPLASMS; NMR IMAGING; PATIENTS; RECTUM; THERAPY

Citation Formats

DeVries, Alexander Friedrich, Piringer, Gudrun, E-mail: gudrun.piringer@hotmail.com, Kremser, Christian, Judmaier, Werner, Saely, Christoph Hubert, Lukas, Peter, and Öfner, Dietmar. Pretreatment Evaluation of Microcirculation by Dynamic Contrast-Enhanced Magnetic Resonance Imaging Predicts Survival in Primary Rectal Cancer Patients. United States: N. p., 2014. Web. doi:10.1016/J.IJROBP.2014.07.042.
DeVries, Alexander Friedrich, Piringer, Gudrun, E-mail: gudrun.piringer@hotmail.com, Kremser, Christian, Judmaier, Werner, Saely, Christoph Hubert, Lukas, Peter, & Öfner, Dietmar. Pretreatment Evaluation of Microcirculation by Dynamic Contrast-Enhanced Magnetic Resonance Imaging Predicts Survival in Primary Rectal Cancer Patients. United States. doi:10.1016/J.IJROBP.2014.07.042.
DeVries, Alexander Friedrich, Piringer, Gudrun, E-mail: gudrun.piringer@hotmail.com, Kremser, Christian, Judmaier, Werner, Saely, Christoph Hubert, Lukas, Peter, and Öfner, Dietmar. Mon . "Pretreatment Evaluation of Microcirculation by Dynamic Contrast-Enhanced Magnetic Resonance Imaging Predicts Survival in Primary Rectal Cancer Patients". United States. doi:10.1016/J.IJROBP.2014.07.042.
@article{osti_22420509,
title = {Pretreatment Evaluation of Microcirculation by Dynamic Contrast-Enhanced Magnetic Resonance Imaging Predicts Survival in Primary Rectal Cancer Patients},
author = {DeVries, Alexander Friedrich and Piringer, Gudrun, E-mail: gudrun.piringer@hotmail.com and Kremser, Christian and Judmaier, Werner and Saely, Christoph Hubert and Lukas, Peter and Öfner, Dietmar},
abstractNote = {Purpose: To investigate the prognostic value of the perfusion index (PI), a microcirculatory parameter estimated from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), which integrates information on both flow and permeability, to predict overall survival and disease-free survival in patients with primary rectal cancer. Methods and Materials: A total of 83 patients with stage cT3 rectal cancer requiring neoadjuvant chemoradiation were investigated with DCE-MRI before start of therapy. Contrast-enhanced dynamic T{sub 1} mapping was obtained, and a simple data analysis strategy based on the calculation of the maximum slope of the tissue concentration–time curve divided by the maximum of the arterial input function was used as a measure of tumor microcirculation (PI), which integrates information on both flow and permeability. Results: In 39 patients (47.0%), T downstaging (ypT0-2) was observed. During a mean (±SD) follow-up period of 71 ± 29 months, 58 patients (69.9%) survived, and disease-free survival was achieved in 45 patients (54.2%). The mean PI (PImean) averaged over the group of nonresponders was significantly higher than for responders. Additionally, higher PImean in age- and gender-adjusted analyses was strongly predictive of therapy nonresponse. Most importantly, PImean strongly and significantly predicted disease-free survival (unadjusted hazard ratio [HR], 1.85 [ 95% confidence interval, 1.35-2.54; P<.001)]; HR adjusted for age and sex, 1.81 [1.30-2.51]; P<.001) as well as overall survival (unadjusted HR 1.42 [1.02-1.99], P=.040; HR adjusted for age and sex, 1.43 [1.03-1.98]; P=.034). Conclusions: This analysis identifies PImean as a novel biomarker that is predictive for therapy response, disease-free survival, and overall survival in patients with primary locally advanced rectal cancer.},
doi = {10.1016/J.IJROBP.2014.07.042},
journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 5,
volume = 90,
place = {United States},
year = {2014},
month = {12}
}